These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 8636795)

  • 1. High-dose chemotherapy for breast cancer.
    Spiridonidis CH; Laufman LR; Rhodes V; Jones J
    J Clin Oncol; 1996 Feb; 14(2):686. PubMed ID: 8636795
    [No Abstract]   [Full Text] [Related]  

  • 2. High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study.
    Zander AR; Krüger W; Kröger N; Damon L; Königmann M; Berdel WE; Gieseking F; Schäfer-Eckart K; Möbus V; Frickhofen N; Wandt H; Illiger HJ; Metzner B; Kolbe K; Wörmann B; Trümper L; Huber C; Hossfeld DK; Maass H; Jonat W
    Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S24-5. PubMed ID: 8899165
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk stratification for high-dose chemotherapy in metastatic breast cancer.
    Subar M
    J Clin Oncol; 1996 Feb; 14(2):686-7. PubMed ID: 8636796
    [No Abstract]   [Full Text] [Related]  

  • 4. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience.
    Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF
    Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose chemotherapy (CTM) for breast cancer.
    Damon LE; Wolf JL; Rugo HS; Gold E; Zander AR; Cassidy M; Cecchi G; Cohen N; Irwin D; Tracy M; Ries CA; Linker CA
    Bone Marrow Transplant; 2000 Aug; 26(3):257-68. PubMed ID: 10967563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer.
    Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D
    Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer.
    Katsumata K; Tomioka H; Kusama M; Aoki T; Koyanagi Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):86-8. PubMed ID: 12764670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine.
    Bezwoda WR; Dansey R; Seymour L
    Oncology; 1989; 46(4):208-11. PubMed ID: 2740063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
    Schmid P; Schippinger W; Nitsch T; Huebner G; Heilmann V; Schultze W; Hausmaninger H; Wischnewsky M; Possinger K
    J Clin Oncol; 2005 Jan; 23(3):432-40. PubMed ID: 15659490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
    Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
    Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer.
    Kumpulainen EJ; Hirvikoski PP; Johansson RT
    Acta Oncol; 2008; 47(1):120-3. PubMed ID: 18097780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of dose-dense chemotherapy in the management of breast cancer.
    Norton L
    Clin Adv Hematol Oncol; 2006 Jan; 4(1):36-7. PubMed ID: 16562368
    [No Abstract]   [Full Text] [Related]  

  • 15. Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer.
    Carlson LE; Koski T; Glück S
    Bone Marrow Transplant; 2001 May; 27(9):989-98. PubMed ID: 11436111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant high-dose chemotherapy with epirubicin and ifosfamide in nodal positive breast cancer.
    Lüftner D; Wagner K; Dingeldein G; Haas A; Sezer O; Mergenthaler HG; Wernecke KD; Possinger K
    Anticancer Res; 1999; 19(4C):3583-90. PubMed ID: 10629656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [High-dose chemotherapy rescued with peripheral blood stem cell transplantation for high-risk patients with breast cancer].
    Kim S; Shiba E; Taguchi T; Kimoto Y; Inoue T; Shimazu K; Takamura Y; Tanji Y; Izukura M; Ogawa H; Sugiyama H; Kubota T; Kimura T; Takai S
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):635-8. PubMed ID: 8678525
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.